Shots:

• The P-III reSURFACE 1 and 2 are extension-study involves assessing of Ilumya (100 &200 mg at 0 and 4wks.) and Ilumya (100 & 200 mg) vs PBO and etanercept (50 mg) respectively. The reSURFACE 1 and reSURFACE 2 Post-Hoc Analyses was conducted to evaluate changes in efficacy of Ilumya in patients with/out metabolic syndrome  
• P-III reSURFACE 1 & 2 extension study@ 100mg: PASI 75/90/100 (82%/56%/28% & 89%/64%/35%) and % of PGA response: (58% & 65%). Post-Hoc Analysis @100mg reSURFACE 1 & 2 with/out metabolic syndrome: PASI 75 (69%/71% & 73%/79%)- PASI 90 (42%/51% & 57%/60%)- PASI 100 (27%/23% & 34%/32%) respectively; Presented at EADV 2019
• Ilumya is an lgG1/k mAb binds with p19 subunit of IL-23 while inhibiting its interaction with the IL-23 receptor further leading inhibition of the release of pro-inflammatory cytokines and chemokines and is approved for mod-to-sev plaque psoriasis in Australia and EU with brand name Ilumetri 

Click here to­ read full press release/ article | Ref: Sun Pharma | Image: PharmaWorld